<DOC>
	<DOCNO>NCT00275652</DOCNO>
	<brief_summary>This trial do see investigational drug , LdT ( Telbivudine ) , safe effective treatment hepatitis B infection . In addition , look comparison effect ( good bad ) LdT lamivudine .</brief_summary>
	<brief_title>A Comparison Drug Telbivudine ( LdT ) Lamivudine Adults With Decompensated Chronic Hepatitis B Evidence Cirrhosis .</brief_title>
	<detailed_description>This study randomize , double-blinded trial look drug Telbivudine ( LdT ) compare drug lamivudine patient chronic hepatitis B evidence Cirrhosis . Interested participant first see screen visit , determine eligibility study . Participants medical history take along physical exam blood draw . Prior receive study drug , participant may require liver biopsy . If one do past 5 year , may possible use result previous biopsy . If participant unable liver biopsy due medical reason , ultrasound , CT , MRI scan may do instead . If image study do past two year , may possible use result test . All eligible participant put one two group chance ( flip coin ) . One group receive 600 mg LdT ( 3 tablet ) plus lamivudine placebo capsule ( 1 sugar pill ) daily . While group receive 100 mg lamivudine ( 1 capsule ) plus 3 LdT tablet ( 3 sugar pill ) daily . Participants take study drug daily total 104 week ( 2 year ) . Participants return clinic visit week 2 , 4 , 8 , 12 , 16 , 24 , 32 , 40 , 48 , 52 , 60 , 68 , 76 , 84 , 92 , 100 , 104 . Participant 's vital sign ( temperature , pulse , weight ) blood sample collect visit . If one year drug , hepatitis b find blood , may stop study drug . Participants continue require return clinic study visit information continue collected condition monitor . If future blood test show hepatitis B virus return , participant tell restart study drug . At end 104 week treatment stop early reason except liver transplant , additional treatment choose hepatitis B , participant ask return clinic every four week 4 month . For return visit clinic , vital sign blood sample collect record . A physical exam last follow-up visit . If study stop due liver transplant , participant ask return clinic visit 4 16 week surgery . At visit , procedure do , review participant 's medical record . Participants involve 2 year 4 month .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients chronic hepatitis b evidence cirrhosis , least 18 70 year old , may eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>